JETREA
Peakocriplasmin
BLAINTRAVITREALINJECTABLEPriority Review
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JETREA (ocriplasmin) is a recombinant protease approved for intravitreal injection to treat vitreomacular adhesion and vitreomacular traction—conditions where the vitreous gel abnormally adheres to the retina. The drug works by enzymatically cleaving proteins that mediate vitreous-retinal adhesion, allowing mechanical separation without surgical intervention.
Peak
JETREA is at peak commercial maturity as a specialized ophthalmic injectable; teams are likely focused on maintaining market access and managing competitive pressure rather than aggressive growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Started Dec 2015
48 enrolled
Diabetic RetinopathyPosterior Vitreous DetachmentDisease Progression
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Started May 2015
62 enrolled
Vitreomacular TractionVitreomacular Adhesion
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
Started Apr 2014
628 enrolled
Vitreomacular TractionVitreomacular Adhesion
Career Relevance
JETREA offers career opportunities primarily in specialty pharmaceutical commercial operations, with emphasis on payer negotiation, physician relationships in ophthalmology, and market access. This is a mature-stage specialty product requiring deep clinical knowledge and relationship management rather than broad market launch skills.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.